COVID-19 update: At this time there are no interruptions in our ability to manufacture and supply product. Our clinical team has instituted virtual video trainings for new pump and CGM customers to ensure continuity of service. Please click here for more information. X

NEWSROOM

Medtronic Launches InPen™ with Real-Time Guardian™ Connect CGM Data – the First Integrated Smart Insulin Pen for People with Diabetes on MDI

Nov. 12, 2020

Nov. 12, 2020 - DUBLIN, Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the launch of InPen™ integrated with real-time1 Guardian Connect™ CGM data. InPen is the first and only FDA-cleared smart2 insulin pen on the market for people on multiple daily injections (MDI). This integrated system now provides real-time glucose readings alongside insulin dose information giving users everything they need to manage their diabetes in one view. Rather than switching between apps, users have the ability to see all their information in real-time, in one view — making it easier to make smarter dosing decisions to manage their sugar levels.

Read more >

Medtronic Commends CMS on Proposed Rule to Expand Medicare Coverage for All CGMs

October 28, 2020

October 28, 2020 – On October 27th, the Centers for Medicare & Medicaid Services (CMS) announced proposed new changes that, if finalized, would expand Medicare coverage for Continuous Glucose Monitors (CGMs) that provide critical information on glucose levels to help people with diabetes better manage their disease. We are very encouraged by CMS’s proposed rule and commend the agency on taking action to help more people with diabetes.

Read more >

Medtronic Announces FDA Approval for Minimed™ 770G Insulin Pump System with Smartphone Connectivity for People with Type 1 Diabetes

September 1, 2020

DUBLIN – September 1, 2020 – Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval of its MiniMed™ 770G hybrid closed loop system. This newest insulin pump system offers the company’s most advanced SmartGuard™ technology, as featured in the MiniMed™ 670G system, with the added benefits of smartphone connectivity and an expanded age indication to children as young as 2.

Read more >

Medtronic Plans To Acquire Smart Insulin Pen Company Companion Medical

August 11, 2020

DUBLIN and SAN DIEGO – August 11, 2020 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the planned acquisition of privately-held Companion Medical, manufacturer of InPen — the only U.S. FDA cleared smart insulin pen system paired with an integrated diabetes management app on the market. The addition of Companion Medical’s InPen to the Medtronic portfolio expands the company’s ability to serve people where they are in their diabetes journey and offer them a unique and expansive ecosystem of support — regardless of how insulin is delivered.

Read more >

Medtronic Expands Diabetes Support Programs to Help Customers Losing Insurance Coverage Due to Job Loss as a Result of COVID-19

May 06, 2020

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced an expansion of the Medtronic Assurance program with a new option to support diabetes customers who have lost their health insurance due to COVID-19-related job loss. Current eligible U.S. customers can now receive a 3-month supply of glucose sensors, infusion sets and reservoirs at no cost.

Read more >

View all Announcements >





Media Inquiries

For media inquiries pertaining to the Diabetes Group of Medtronic, please contact:

Janet Cho
Sr Director, Global Communications
818-576-5014
janet.cho@medtronic.com

Pamela Reese
Director, Communications
818-576-3398
pamela.s.reese@medtronic.com

For all other media inquiries please select the appropriate Global Public and Media Relations contact

Media Kits